Clinical Trial Update: Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update on ISIS 113715 assessing safety, tolerability, and activity in people with Type 2 Diabetes Mellitus; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ISIS 113715

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED